airway infections respiratory viral infections
Conditions
Interventions
None listed
Sponsors
Julius Clinical
Eligibility
Age
65 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Aged 65 years or older 2. Cognitive competence such that one understands the study concept and requirements, can make a voluntary decision to participate in the study, and give informed consent 3. Willing and able to complete the study procedures 4. Giving informed consent 5. Having access to a mobile phone or landline phone 6. Generally healthy and without chronic disease that would likely require hospitalisation during the course of the study, as per the investigator*s clinical judgment
Exclusion criteria
Exclusion criteria: 1. Residing in a short- or long-term care facility 2. Having a terminal illness, as judged by the investigator 3. Receiving anti-cancer treatment 4. Having a B-cell disorder or blood or bleeding disorder, including anaemia, haemophilia, Factor II, V, VII, X, or XII deficiencies, Von Willebrand*s disease, tendency to bruise easily, blood cancer, taking blood thinners, or otherwise unable to give blood 5. Being a regular blood donor 6. Any known factor, condition, or disease that might interfere with compliance, study conduct or interpretation of the results, as deemed by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Incidence of pauci-symptomatic and symptomatic influenza-like illness/acute respiratory illness (ILI/ARI) episodes due to influenza virus, SARS-CoV-2 or RSV (see Definitions) based on clinical symptoms and laboratory-based multiplex PCR testing of nasopharyngeal/throat swabs collected at the time of infection - Incidence and aetiology of co-infections in pauci-symptomatic and symptomatic laboratory-confirmed influenza, SARS-CoV-2, or RSV - Occurrence of re-infections with influenza, SARS-CoV-2, or RSV. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Immunological and molecular characteristics of upper respiratory tract samples, including nasal swabs, nasosorption samples and saliva samples collected from subjects whilst having a PCR-confirmed pauci-symptomatic or symptomatic infection (ILI/ARI) caused by influenza virus, SARS-CoV-2, or RSV, or when infection free (no symptoms and no virus detected in PCR) - Serum IgG and saliva IgA, IgG and IgM antibody responses against different respiratory viruses including influenza virus, SARS-CoV-2 and RSV at baseline and over the course of the study including pauci-symptomatic and symptomatic ILI/ARI episodes | — |
Countries
Netherlands
Outcome results
None listed